Fresenius Medical Care AG... (FMS)
Company Description
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally.
It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products.
In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services.
The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents.
As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries.
Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Country | DE |
IPO Date | Sep 17, 1996 |
Industry | Medical - Care Facilities |
Sector | Healthcare |
Employees | 111,513 |
CEO | Helen Giza |
Contact Details
Address: Else-KrOener Strasse 1 Bad Homburg, DE | |
Website | https://www.freseniusmedicalcare.com |
Stock Details
Ticker Symbol | FMS |
Exchange | NYSE |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001333141 |
CUSIP Number | 358029106 |
ISIN Number | US3580291066 |
Employer ID | 00-0000000 |
SIC Code | 8090 |
Key Executives
Name | Position |
---|---|
Craig Cordola FACHE, M.B.A., M.H.A. | Chief Executive Officer of Care Delivery & Member of Management Board |
Dr. Katarzyna Mazur-Hofsab Ph.D. | Chief Executive Officer of Care Enablement & Member of Management Board |
Helen Giza | Chair of Management Board & Chief Executive Officer |
Martin Fischer | Chief Financial Officer & Member of the Management Board |
Dr. Dominik Heger | Executive Vice President and Head of Investor Relations, Strategic Development & Communications |
Dr. Franklin W. Maddux F.A.C.P. | Global Chief Medical Officer & Member of Management Board |
Dr. Gail-Suzanne Brown | Senior Vice President of Research & Development |
Joachim Weith | Senior Vice President of Corporate Communications & Governmental Affairs |
Jorg Haring | Member of the Management Board, Global Head of Legal,Compliance & Human Resources and Labor Director |
Roberto Fuste | Executive Advisor for Regional Strategy |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 10, 2025 | SCHEDULE 13D/A | [Amend] Filing |
Mar 06, 2025 | SCHEDULE 13D/A | [Amend] Filing |
Feb 25, 2025 | 6-K | Filing |
Feb 25, 2025 | IRANNOTICE | Filing |
Feb 25, 2025 | 20-F | Filing |
Feb 25, 2025 | 6-K | Filing |
Feb 24, 2025 | 6-K | Filing |
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Dec 20, 2024 | 6-K | Filing |
Dec 18, 2024 | 6-K | Filing |